Status:

NOT_YET_RECRUITING

Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve

Lead Sponsor:

Institut für Pharmakologie und Präventive Medizin

Conditions:

Transcatheter Aortic Valve Replacement (TAVR)

Aortic-Stenosis

Eligibility:

All Genders

18+ years

Brief Summary

Evaluation of clinical outcomes and valve performance of the SAPIEN 3 Ultra Resilia (S3UR) valve over 10 years.

Detailed Description

Transcatheter aortic valve replacement (TAVI) has become the gold standard treatment for moderate-to-high risk elderly patients with severe symptomatic aortic stenosis. Based on the results of randomi...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Adult patients (≥18 years)
  • Patients with severe aortic stenosis undergoing transfemoral TAVI on their native valve with S3UR valve
  • Patient is willing to attend the follow-up visits up to 10 years at the center
  • Exclusion criteria:
  • Lack of written informed consent
  • Emergency procedure
  • Pregnancy at time of TAVI
  • Critieria for long-term observation (1y-10y):
  • Technical success at exit from procedure room (VARC-3):
  • Freedom from mortality
  • Successful access, delivery of the device, and retrieval of the delivery system
  • Correct positioning of a single prosthetic heart valve into the proper anatomical location
  • Freedom from surgery or intervention related to the device (excluding permanent pacemaker or PTA and stenting without major bleeding) or to a major vascular or access related, or cardiac structural complication
  • Absence of the following severe procedural and in-hospital complications (VARC-3 definitions):
  • All stroke
  • Bleeding type 3-4
  • Myocardial infarction
  • Need for a second valve
  • Valve embolization
  • Coronary obstruction
  • Annular rupture

Exclusion

    Key Trial Info

    Start Date :

    September 1 2025

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    September 30 2037

    Estimated Enrollment :

    500 Patients enrolled

    Trial Details

    Trial ID

    NCT06953206

    Start Date

    September 1 2025

    End Date

    September 30 2037

    Last Update

    June 29 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Heart and Diabetes Center North Rhine-Westphalia

    Bad Oeynhausen, North Rhine-Westphalia, Germany, 32545

    Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve | DecenTrialz